Journal
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Volume 35, Issue 8, Pages 1950-1956Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pnpbp.2011.07.011
Keywords
ERK; Olanzapine; Oligodendrocyte precursor cell; Schizophrenia
Funding
- Japanese Ministry of Education, Science, Sports, and Culture
- Tsumura Pharmaceutical Co.
- Dainippon Sumitomo Pharmaceutical Co.
- Grants-in-Aid for Scientific Research [23590221] Funding Source: KAKEN
Ask authors/readers for more resources
In the developing brain, oligodendrocyte progenitor cells (OPCs) proliferate, migrate, and differentiate into mature oligodendrocytes (OLs) capable of myelinating axons. Recently, OPCs have been identified as an abundant and widespread population in the adult as well as in the developing animal. Current research indicates that these OPCs in the adult brain can proliferate and differentiate into myelinating OLs, albeit with different potentialities from those in developing animals. Multiple lines of evidence, from neuroimaging, postmortem, and genetic association studies, have implicated OL and myelin dysfunction in the pathogenesis of schizophrenia. If altered OL function is involved in pathogenesis, OPCs may thus respond to antipsychotic drugs during the recovery process. In the present study, we used primary OPC cultures from optic nerve of newborn Wistar rat pups to investigate the direct effects of haloperidol (HPD; a typical antipsychotic) and olanzapine (012; an atypical antipsychotic) on the proliferation and differentiation of OPCs. Our results showed that 1) 012 treatment significantly increased the number of viable OPCs when compared to HPD treatment at relatively high concentrations, 2) 012 treatment suppressed the expression of myelin basic protein (MBP), and to a greater extent than HPD treatment, and 3) these pharmacological effects may be mediated via the ERK signaling pathway. Our findings suggest a glial mechanism for the antipsychotic action of 012, and a role for oligodendrocyte-lineage cells in the pathogenesis and treatment of schizophrenia. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available